Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Pyrilamine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH1 known ✓ | P35367 | 3/20 | 0.95 |
| ▸ | LMNA | P02545 | 4/20 | 0.95 |
| ▸ | CHRM2 | P08172 | 4/20 | 0.95 |
| ▸ | ADRA2A | P08913 | 4/20 | 0.95 |
| ▸ | DRD1 | P21728 | 4/20 | 0.95 |
| ▸ | SLC6A4 | P31645 | 4/20 | 0.95 |
| ▸ | SLC6A3 | Q01959 | 4/20 | 0.95 |
| ▸ | KCNH2 | Q12809 | 4/20 | 0.95 |
| ▸ | HTR2A | P28223 | 3/20 | 0.95 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.95 |
| ▸ | CYP2D6 | P10635 | 3/20 | 0.95 |
| ▸ | OPRM1 | P35372 | 3/20 | 0.95 |
| ▸ | TSHR | P16473 | 3/20 | 0.95 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.95 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.95 |
| ▸ | HTR2C | P28335 | 2/20 | 0.95 |
| ▸ | HTR2B | P41595 | 2/20 | 0.95 |
| ▸ | MEN1 | O00255 | 2/20 | 0.95 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.95 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.95 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Pyrilamine SCHEMBL4075657 | 0.97 | LMNA (0.90) | LMNACHRM2ADRA2ADRD1SLC6A4 | |
| Pyrilamine SCHEMBL19114 | 0.97 | LMNA (1.00) | LMNACHRM2ADRA2ADRD1SLC6A4 | |
| Pyrilamine SCHEMBL29444024 | 0.97 | LMNA (1.00) | LMNACHRM2ADRA2ADRD1SLC6A4 | |
| Pyrilamine SCHEMBL22118219 | 0.96 | LMNA (0.97) | LMNACHRM2ADRA2ADRD1SLC6A4 | |
| Pyrilamine SCHEMBL28823277 | 0.96 | LMNA (0.97) | LMNACHRM2ADRA2ADRD1SLC6A4 | |
| Pyrilamine SCHEMBL4891045 | 0.96 | LMNA (0.97) | LMNACHRM2ADRA2ADRD1SLC6A4 | |
| Pyrilamine SCHEMBL28350675 | 0.96 | LMNA (0.97) | LMNACHRM2ADRA2ADRD1SLC6A4 | |
| Pyrilamine SCHEMBL28086659 | 0.95 | LMNA (0.95) | LMNACHRM2ADRA2ADRD1SLC6A4 | |
| Pyrilamine SCHEMBL4450392 | 0.90 | CHRM2 (0.86) | LMNACHRM2ADRA2ADRD1SLC6A4 | |
| Pyrilamine SCHEMBL28032666 | 0.90 | LMNA (0.86) | LMNACHRM2ADRA2ADRD1SLC6A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 188 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240199713-A1 | MODIFIED POLYPEPTIDES AND USES THEREOF | MACQUARIE UNIVERSITY (AU) | 2024-06-20 | — | — | US | disclosed |
| US-11945841-B2 | Headless hemagglutin influenza vaccine | GEROGIA STATE UNIVERSITY RESEARCH FOUNDATION, INC. (US) | 2024-04-02 | — | — | US | disclosed |
| EP-4326340-A1 | MODIFIED POLYPEPTIDES AND USES THEREOF | Macquarie University (AU) | 2024-02-28 | — | — | EP | disclosed |
| EP-3582754-B1 | COMPOSITION AND METHODS FOR PREVENTING RADIATION INJURY AND PROMOTING TISSUE REGENERATION | XEQUEL BIO INC (US) | 2024-01-10 | — | — | EP | disclosed |
| US-20240000885-A1 | COMPOSITIONS AND METHODS FOR TARGETING THE INTERACTION OF HOST MYO5B+D AND CORONAVIRUS M PROTEINS | NATIONAL SCIENCE FOUNDATION | 2024-01-04 | — | — | US | disclosed |
| US-11850283-B2 | Liponucleotide-based therapy for asthma | OHIO STATE INNOVATION FOUNDATION (US) | 2023-12-26 | — | — | US | disclosed |
| WO-2023220614-A2 | RECOMBINANT SUBUNIT BASED UNIVERSAL INFLUENZA AND RESPIRATORY VIRUS VACCINES | GEORGIA STATE UNIVERSITY RESEARCH FOUNDATION, INC. (US) | 2023-11-16 | — | — | WO | disclosed |
| WO-2023192218-A1 | REGENERATIVE HELMINTH CONTAINING COMPOSITIONS AND USES THEREOF | THE JOHNS HOPKINS UNIVERSITY (US) | 2023-10-05 | — | — | WO | disclosed |
| WO-2023092001-A1 | TARGETED DRUG DELIVERY-RELEASE AND KILLING OF DRUG RESISTANT TUMORS AND PATHOGENS | RUBHU BIOLOGICS, INC. (US) | 2023-05-25 | — | — | WO | disclosed |
| US-20230147795-A1 | COMPOSITION AND METHODS FOR PREVENTING RADIATION INJURY AND PROMOTING TISSUE REGENERATION | XEQUEL BIO, INC. | 2023-05-11 | — | — | US | disclosed |
| US-20090215665-A1 | COMPOSITIONS AND METHODS FOR PROMOTING WOUND HEALING AND TISSUE REGENERATION | MEDICAL UNIVERSITY OF SOUTH CAROLINA | 2009-08-27 | — | — | US | disclosed |
| EP-2091964-A2 | TARGETING NBS1-ATM INTERACTION TO SENSITIZE CANCER CELLS TO RADIOTHERAPY AND CHEMOTHERAPY | Southern Research Institute (US) | 2009-08-26 | — | — | EP | disclosed |
| EP-2026777-A2 | PERIPHERAL AND NEURAL INFLAMMATORY CROSSTALK | University of Rochester (US) | 2009-02-25 | — | — | EP | disclosed |
| WO-2009018429-A2 | TREATMENT OF CANCER VIA TARGETING OF IL-13 RECEPTOR-α2 | THE GOVERNMENT OF THE UNITED STATES OF AMERICA, ASREPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALT OF HUMAN SERVICES, NATIONAL INSTITUTES OF HEALT (US) | 2009-02-05 | — | — | WO | disclosed |
| WO-2008157840-A2 | ALPHA CONNEXIN C-TERMINAL (ACT) PEPTIDES FOR TREATING AGE-RELATED MACULAR DEGENERATION | MUSC FOUNDATION FOR RESEARCH DEVELOPMENT (US) | 2008-12-24 | — | — | WO | disclosed |
| WO-2008125902-A2 | PERIPHERAL AND NEURAL INFLAMMATORY CROSSTALK | UNIVERSITY OF ROCHESTER (US) | 2008-10-23 | — | — | WO | disclosed |
| WO-2008054726-A2 | TARGETING NBS1-ATM INTERACTION TO SENSITIZE CANCER CELLS TO RADIOTHERAPY AND CHEMOTHERAPY | SOUTHERN RESEARCH INSTITUTE (US) | 2008-05-08 | — | — | WO | disclosed |
| US-20080095819-A1 | Antiproliferative agents; connexins; reducing density of astrocytes; increasing density of neurons; hair growth; cosmetic surgery | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2008-04-24 | — | — | US | disclosed |
| EP-1827480-A2 | COMPOSITIONS AND METHODS FOR PROMOTING WOUND HEALING AND TISSUE REGENERATION | MUSC Foundation For Research Development (US) | 2007-09-05 | — | — | EP | disclosed |
| WO-2006069181-A2 | COMPOSITIONS AND METHODS FOR PROMOTING WOUND HEALING AND TISSUE REGENERATION | MUSC FOUNDATION FOR RESEARCH DEVELOPMENT (US) | 2006-06-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090215665-A1 | COMPOSITIONS AND METHODS FOR PROMOTING WOUND HEALING AND TISSUE REGENERATION | MMP8, MMP1, COL2A1 | HRH1 4177/4885LMNA 1714/4885CHRM2 4604/4885 |
| US-20080095819-A1 | Antiproliferative agents; connexins; reducing density of astrocytes; increasing density of neurons; hair growth; cosmetic surgery | GAP43, GJB2, GJA1 | HRH1 4025/4885LMNA 2096/4885CHRM2 1953/4885 |
| US-20230147795-A1 | COMPOSITION AND METHODS FOR PREVENTING RADIATION INJURY AND PROMOTING TISSUE REGENERATION | MMP1, COL2A1, MMP8 | HRH1 4014/4885LMNA 622/4885CHRM2 3543/4885 |
| US-11850283-B2 | Liponucleotide-based therapy for asthma | PLA2G4C, CHKB, PLA2G4A | HRH1 319/4885LMNA 1299/4885CHRM2 343/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.